Literature DB >> 24033560

Antitumor efficacy of C-X-C motif chemokine ligand 14 in hepatocellular carcinoma in vitro and in vivo.

Weilin Wang1, Pengfei Huang, Lufei Zhang, Jianfeng Wei, Qingsong Xie, Qiang Sun, Xiaohu Zhou, Haiyang Xie, Lin Zhou, Shusen Zheng.   

Abstract

C-X-C motif chemokine ligand 14 (CXCL14) is a novel gene that is expressed in many normal cells but is absent from or expressed at very low levels in cancerous tissues such as head and neck squamous cell carcinoma (HNSCC), prostate cancer, and pancreatic cancer. However, the relationship between CXCL14 and hepatocellular carcinoma (HCC) remains unclear. Therefore, the exact function of CXCL14, which may modulate antitumor immune responses in certain cancers, was evaluated. CXCL14 was downregulated in HCC tissues compared to adjacent normal tissues. Moreover, overexpression of CXCL14 had an inhibitory effect on cell proliferation, induced apoptosis and inhibited the invasion of HCC cells in vitro. Upregulation of CXCL14 by lentivirus also significantly suppressed the growth of subcutaneous tumors in nude mice in vivo. We further demonstrated that the loss of CXCL14 expression was regulated by promoter hypermethylation. CXCL14 induced tumor cell apoptosis through both the mitochondrial and nuclear apoptosis pathways. CXCL14 suppressed tumor cell proliferation through regulation of the cell cycle by downregulation of cyclins and cyclin-dependent kinases. In conclusion, CXCL14 plays a pivotal role as a potential tumor suppressor in HCC. The re-expression or upregulation of this gene may provide a novel strategy in HCC therapy in the future.
© 2013 Japanese Cancer Association.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24033560      PMCID: PMC7656557          DOI: 10.1111/cas.12279

Source DB:  PubMed          Journal:  Cancer Sci        ISSN: 1347-9032            Impact factor:   6.716


  40 in total

1.  Reactive oxygen species (ROS) reduce the expression of BRAK/CXCL14 in human head and neck squamous cell carcinoma cells.

Authors:  Yojiro Maehata; Shigeyuki Ozawa; Kyo Kobayashi; Yasumasa Kato; Fumihiko Yoshino; Chihiro Miyamoto; Kazuhito Izukuri; Eiro Kubota; Ryu-Ichiro Hata; Masaichi-Chang-Il Lee
Journal:  Free Radic Res       Date:  2010-08

2.  An intronic polymorphism rs2237062 in the CXCL14 gene influences HBV-related HCC progression in Chinese population.

Authors:  Xing Gu; Hao Wang; Aihua Wang; Tonghai Dou; Peng Qi; Qiang Ji; Hui Li; Chunfang Gao
Journal:  Mol Biol Rep       Date:  2011-05-10       Impact factor: 2.316

3.  B cell- and monocyte-activating chemokine (BMAC), a novel non-ELR alpha-chemokine.

Authors:  M A Sleeman; J K Fraser; J G Murison; S L Kelly; R L Prestidge; D J Palmer; J D Watson; K D Kumble
Journal:  Int Immunol       Date:  2000-05       Impact factor: 4.823

Review 4.  Molecular targeted therapies in hepatocellular carcinoma.

Authors:  Josep M Llovet; Jordi Bruix
Journal:  Hepatology       Date:  2008-10       Impact factor: 17.425

Review 5.  Hepatocellular carcinoma.

Authors:  Josep M Llovet; Andrew Burroughs; Jordi Bruix
Journal:  Lancet       Date:  2003-12-06       Impact factor: 79.321

6.  Isolation of the human cdk2 gene that encodes the cyclin A- and adenovirus E1A-associated p33 kinase.

Authors:  L H Tsai; E Harlow; M Meyerson
Journal:  Nature       Date:  1991-09-12       Impact factor: 49.962

Review 7.  Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival.

Authors:  Josep M Llovet; Jordi Bruix
Journal:  Hepatology       Date:  2003-02       Impact factor: 17.425

8.  In human hepatocellular carcinoma in cirrhosis proliferating cell nuclear antigen (PCNA) is involved in cell proliferation and cooperates with P21 in DNA repair.

Authors:  Laura Gramantieri; Davide Trerè; Pasquale Chieco; Michela Lacchini; Catia Giovannini; Fabio Piscaglia; Antonino Cavallari; Luigi Bolondi
Journal:  J Hepatol       Date:  2003-12       Impact factor: 25.083

Review 9.  Rb inactivation in cell cycle and cancer: the puzzle of highly regulated activating phosphorylation of CDK4 versus constitutively active CDK-activating kinase.

Authors:  Sabine Paternot; Laurence Bockstaele; Xavier Bisteau; Hugues Kooken; Katia Coulonval; Pierre P Roger
Journal:  Cell Cycle       Date:  2010-02-12       Impact factor: 4.534

10.  Role of tumor associated fibroblasts in human liver regeneration, cirrhosis, and cancer.

Authors:  Daniela Cesselli; Antonio Paolo Beltrami; Alessandra Poz; Stefania Marzinotto; Elisa Comisso; Natascha Bergamin; Evgenia Bourkoula; Anja Pucer; Elisa Puppato; Barbara Toffoletto; Marisa Sorrentino; Umberto Baccarani; Claudio Avellini; Carlo Alberto Beltrami
Journal:  Int J Hepatol       Date:  2011-12-01
View more
  26 in total

Review 1.  Chemokines and their receptors play important roles in the development of hepatocellular carcinoma.

Authors:  Chun-Min Liang; Long Chen; Heng Hu; Hui-Ying Ma; Ling-Ling Gao; Jie Qin; Cui-Ping Zhong
Journal:  World J Hepatol       Date:  2015-06-08

2.  Regulation of gene expression in HBV- and HCV-related hepatocellular carcinoma: integrated GWRS and GWGS analyses.

Authors:  Xu Zhou; Hua-Qiang Zhu; Jun Lu
Journal:  Int J Clin Exp Med       Date:  2014-11-15

3.  CD169-positive macrophages enhance abscopal effect of radiofrequency ablation therapy in liver cancer.

Authors:  Xiaojia Song; Na Li; Yuan Liu; Zehua Wang; Tixiao Wang; Siyu Tan; Chunyang Li; Chunhong Qiu; Lifen Gao; Kenichi Asano; Masato Tanaka; Xiaohong Liang; Xinyong Liu; Chunhong Ma
Journal:  Transl Oncol       Date:  2021-12-06       Impact factor: 4.243

4.  High Level of Ubiquitin Conjugate Enzyme E2O Indicates Poor Prognosis of Patients with Hepatocellular Carcinoma.

Authors:  Si-Yu Lan; Yang Ding; Chun Wang; Jun Fang; Chao Ren; Jia-Liang Liu; Hui Kang; Ying Chang
Journal:  Curr Med Sci       Date:  2022-10-21

5.  Antitumor efficacy of C-X-C motif chemokine ligand 14 in hepatocellular carcinoma in vitro and in vivo.

Authors:  Weilin Wang; Pengfei Huang; Lufei Zhang; Jianfeng Wei; Qingsong Xie; Qiang Sun; Xiaohu Zhou; Haiyang Xie; Lin Zhou; Shusen Zheng
Journal:  Cancer Sci       Date:  2013-10-14       Impact factor: 6.716

6.  Antitumor efficacy of CC motif chemokine ligand 19 in colorectal cancer.

Authors:  Jun Lu; Jingkun Zhao; Hao Feng; Puxiongzhi Wang; Zhuo Zhang; Yaping Zong; Junjun Ma; Minhua Zheng; Aiguo Lu
Journal:  Dig Dis Sci       Date:  2014-04-05       Impact factor: 3.199

Review 7.  The multifarious roles of the chemokine CXCL14 in cancer progression and immune responses.

Authors:  Joseph A Westrich; Daniel W Vermeer; Paul L Colbert; William C Spanos; Dohun Pyeon
Journal:  Mol Carcinog       Date:  2020-03-24       Impact factor: 4.784

8.  Serum levels of chemokines CCL4 and CCL5 in cirrhotic patients indicate the presence of hepatocellular carcinoma.

Authors:  M Sadeghi; I Lahdou; H Oweira; V Daniel; P Terness; J Schmidt; K-H Weiss; T Longerich; P Schemmer; G Opelz; A Mehrabi
Journal:  Br J Cancer       Date:  2015-08-13       Impact factor: 7.640

9.  Relatively Small Contribution of Methylation and Genomic Copy Number Aberration to the Aberrant Expression of Inflammation-Related Genes in HBV-Related Hepatocellular Carcinoma.

Authors:  Dianke Yu; Guosheng Zhang; Xudong Huang; Chen Wu; Wen Tan; Yan Qiao; Jiang Chang; Hong Zhao; Xinyu Bi; Jianqiang Cai; Yun Li; Dongxin Lin
Journal:  PLoS One       Date:  2015-05-12       Impact factor: 3.240

10.  The effect of chemokine CC motif ligand 19 on the proliferation and migration of hepatocellular carcinoma.

Authors:  Ke-Qin Luo; Yi-Ni Shi; Ji-Cai Peng
Journal:  Tumour Biol       Date:  2014-09-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.